Gene Enlightenment's iNKT Cell Therapy GKL-006 Receives IND Acceptance for New Indication in Post-Surgical High-Risk Recurrence Prevention of Hepatocellular Carcinoma

Jun 12, 2024 10:43 CST Updated 10:43

Gene Key

Developer of Immune Cell Product Technologies and Provider of Clinical Application Services

Recently, according to the CDE official website, the IND application for another indication of "GKL-006 Injection," a cell therapy product by Beijing Gene Key Life Technology Co., Ltd. ("Gene Key"), intended to prevent high-risk recurrence in patients with primary hepatocellular carcinoma after radical resection, has been accepted.

GKL-006 Injection has obtained the clinical trial approval from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) in November 2023 for the indication of unresectable primary hepatocellular carcinoma, and the clinical trial is currently underway.

E.N.D

In order to allow everyone to learn and communicate with each other better,"WeChat Official Account 'Cell Gene Therapy' Team"A WeChat group for cell therapy and gene therapy has been established. Interested friends can scan the QR code below to add the editor's WeChat and join the cell therapy and gene therapy discussion group.。

Article Recommendation(Click on the article title below to open the original text)：

Gene therapy company Beijing Gene Key Life Technology Co., Ltd. announces completion of B+ round financing

12 Cases of CAR-T Cell Therapy in Lupus Erythematosus Patients Show Significant Efficacy

Cai Lei's Breakthrough Achieves New Progress

Overview of the Cell and Gene Therapy Industry and Industrial Layout in China

People's Daily: Cell Therapy Pushes the Treatment of Difficult and Severe Diseases into a New Stage!

A Dual Victory in Market and Efficacy: The Top Ten Best-Selling Drugs in the Cell and Gene Therapy Field in 2023

Research Report: Exploration of Opportunities in Advanced Technologies and Industrialization of Innovative Drugs

Over 90% of Patients Show Tumor Reduction! AstraZeneca's Hepatocellular Carcinoma Targeted CAR-T Therapy Shines with Impressive Data Release

Origin Biosciences Announces Long-term Follow-up Results of GPRC5D CAR-T OriCAR-017

China's First Batch of CAR-T Therapies "Pay-by-Outcome" Results Released

Seven Companies in China Complete New Round of Financing, Focusing on Cell and Gene Therapy Fields

One Treatment, Lifetime Cure! First LNP-mRNA In Vivo Gene Editing Therapy Announces Long-Term Positive Data from Phase 1 Study

The Second Case of Pig Kidney Transplantation Globally: Patient "Forced" to Remove Pig Kidney

CRO, CDMO: The Winter Has Passed, Dawn Is About to Break

Heavyweight! The world's first non-COVIDmRNA Vaccine Approved for Marketing

Another Chinese CXO Company Targeted by the U.S.

Fosun Pharma Considers Privatizing Henlius

World's First! Beijing Union Medical College Hospital Publishes Phase 1 Study Results of Neural Stem Cell Transplantation via Nasal Mucosa for Parkinson's Disease Treatment

Nearly 70% of Patients Show Complete Cancer Cell Disappearance! Bristol-Myers Squibb’s CAR-T Therapy Receives Another FDA Accelerated Approval

FDA Releases New Draft Guidance to Accelerate Approval of Drugs like Cell and Gene Therapies

Multinational pharmaceutical companies continue to snap up China's innovative drugs

RNAi Therapy Promises to Open Up New Strategies for Long-Acting Weight Loss Treatments

Are leading Chinese CXOs like Wuxi AppTec starting to shift their focus?

100% of Patients Achieved Remission! Latest Positive Clinical Results of CAR-T Therapy Announced

1.25 Trillion! Beijing Issues Policy to Support Rapid Industrial Growth in Cell Gene Therapy, Synthetic Biology, and More

Enkaisai Universal NK Approved for Clinical Trials, Targeting Solid Tumors

Latest 24-Week Clinical Research Data of ART001, the First In Vivo Gene Editing Product in China to Enter IIT Clinical Study

Disclaimer: The content is sourced from the CDE official website, Beijing Gene Key Life Technology Co., Ltd's official channels, etc. All content in this article is for reference only and does not constitute any advice.